These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 34397539)

  • 41. Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy.
    Kazi DS; Bellows BK; Baron SJ; Shen C; Cohen DJ; Spertus JA; Yeh RW; Arnold SV; Sperry BW; Maurer MS; Shah SJ
    Circulation; 2020 Apr; 141(15):1214-1224. PubMed ID: 32078382
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tafamidis therapy in transthyretin amyloid cardiomyopathy: a narrative review from clinical trials and real-world evidence.
    Ogieuhi IJ; Ugiomoh OM; Muzofa K; Callender K; Ayodeji JD; Nnekachi NP; Thiyagarajan B; Uduigwome EO; Kapoor A; Odoeke MC; Mohamed RGH; Idahor C
    Egypt Heart J; 2024 Jul; 76(1):90. PubMed ID: 38985360
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy.
    Nuvolone M; Girelli M; Merlini G
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555787
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis.
    Bézard M; Kharoubi M; Galat A; Poullot E; Guendouz S; Fanen P; Funalot B; Moktefi A; Lefaucheur JP; Abulizi M; Deux JF; Gendre T; Audard V; El Karoui K; Canoui-Poitrine F; Zaroui A; Itti E; Teiger E; Planté-Bordeneuve V; Oghina S; Damy T
    Eur J Heart Fail; 2021 Feb; 23(2):264-274. PubMed ID: 33094885
    [TBL] [Abstract][Full Text] [Related]  

  • 45.
    Tahara N; Lairez O; Endo J; Okada A; Ueda M; Ishii T; Kitano Y; Lee HE; Russo E; Kubo T
    ESC Heart Fail; 2022 Feb; 9(1):251-262. PubMed ID: 34841715
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of transthyretin cardiac amyloidosis.
    Bampatsias D; Wardhere A; Maurer MS
    Curr Opin Cardiol; 2024 Sep; 39(5):407-416. PubMed ID: 38652263
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Narrative review of pharmacotherapy for transthyretin cardiac amyloid.
    Cruz Rodriguez JB; Tallaj JA
    Ann Transl Med; 2021 Mar; 9(6):519. PubMed ID: 33850916
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tafamidis: A Review in Transthyretin Amyloid Cardiomyopathy.
    Lamb YN
    Am J Cardiovasc Drugs; 2021 Jan; 21(1):113-121. PubMed ID: 33469827
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tafamidis and quality of life in people with transthyretin amyloid cardiomyopathy in the study ATTR-ACT: A plain language summary.
    Hanna M; Damy T; Grogan M; Stewart M; Gundapaneni B; Sultan MB; Maurer MS
    Future Cardiol; 2022 Mar; 18(3):165-172. PubMed ID: 34779246
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis.
    Maurer MS; Bokhari S; Damy T; Dorbala S; Drachman BM; Fontana M; Grogan M; Kristen AV; Lousada I; Nativi-Nicolau J; Cristina Quarta C; Rapezzi C; Ruberg FL; Witteles R; Merlini G
    Circ Heart Fail; 2019 Sep; 12(9):e006075. PubMed ID: 31480867
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Real-World Efficacy of Tafamidis in Patients With Transthyretin Amyloidosis and Heart Failure.
    Ghoneem A; Bhatti AW; Khadke S; Mitchell J; Liu J; Zhang K; Trachtenberg B; Wechalekar A; Cheng RK; Baron SJ; Nohria A; Lenihan D; Ganatra S; Dani SS
    Curr Probl Cardiol; 2023 Jun; 48(6):101667. PubMed ID: 36828040
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Patisiran for the Treatment of Transthyretin-mediated Amyloidosis with Cardiomyopathy.
    Ioannou A; Fontana M; Gillmore JD
    Heart Int; 2023; 17(1):27-35. PubMed ID: 37456349
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy.
    Maestro-Benedicto A; Vela P; de Frutos F; Mora N; Pomares A; Gonzalez-Vioque E; Briceño A; Cabrera E; Cobo-Marcos M; Dominguez F; Gonzalez-Lopez E; Segovia J; Lara-Pezzi E; Garcia-Pavia P
    Eur J Heart Fail; 2022 Dec; 24(12):2367-2373. PubMed ID: 35999650
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis.
    Antonopoulos AS; Panagiotopoulos I; Kouroutzoglou A; Koutsis G; Toskas P; Lazaros G; Toutouzas K; Tousoulis D; Tsioufis K; Vlachopoulos C
    Eur J Heart Fail; 2022 Sep; 24(9):1677-1696. PubMed ID: 35730461
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cardiovascular Involvement in Transthyretin Cardiac Amyloidosis.
    Lioncino M; Monda E; Palmiero G; Caiazza M; Vetrano E; Rubino M; Esposito A; Salerno G; Dongiglio F; D'Onofrio B; Verrillo F; Cerciello G; Manganelli F; Pacileo G; Bossone E; Golino P; Calabrò P; Limongelli G
    Heart Fail Clin; 2022 Jan; 18(1):73-87. PubMed ID: 34776085
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [What gnaws at the heart and gets on the nerves].
    Kristen AV
    Internist (Berl); 2018 Nov; 59(11):1208-1213. PubMed ID: 30039176
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Emerging Therapies for Transthyretin Amyloidosis.
    Tsoi MR; Lin JH; Patel AR
    Curr Oncol Rep; 2023 Jun; 25(6):549-558. PubMed ID: 36943555
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tafamidis for the Treatment of Hereditary Transthyretin Amyloid Cardiomyopathy: A Case Report.
    Fujita T; Inomata T; Kaida T; Iida Y; Ikeda Y; Nabeta T; Ishii S; Maekawa E; Naruke T; Koitabashi T; Kitamura E; Sekijima Y; Ako J
    Cardiology; 2017; 137(2):74-77. PubMed ID: 28152524
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Illustrative review of cardiac amyloidosis by multimodality imaging.
    Tanaka H
    Heart Fail Rev; 2023 Jan; 28(1):113-122. PubMed ID: 35474404
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular mechanisms and emerging therapies in wild-type transthyretin amyloid cardiomyopathy.
    Wu D; Chen W
    Heart Fail Rev; 2024 Mar; 29(2):511-521. PubMed ID: 38233673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.